House passes bill to reauthorize rare pediatric PRV program Read in browser

Thank you for reading, dupa dupackia! basic Subscription UPGRADE

M Tue W Th F 2 December, 2025

If reaching biopharma’s most influential decision-makers is a 2026 priority, this live Q&A will show you where Endpoints is headed — and how brands are turning that reach into impact. Join founder and CEO Arsalan Arif for an insider session built for marketing and communications professionals. Register now.

presented by Writ­ing the Next Chap­ter in CLL Care: Bridg­ing Gaps Through In­no­va­tion and In­sights

spotlight Biopharma Sentiment Index | Q4 2025 Introducing Endpoints Signal — intelligence for fresh biopharma insights Half of biopharma is now "heavy AI" — and they see a different future | Signal Pulse Report

news Imvax shares Phase 2b data for glioblastoma treatment, plans to meet with FDA Swiss biotech plots Series B raise to advance Alzheimer’s drug into Phase 2 House passes bill to reauthorize rare pediatric PRV program; Senate next Janux’s prostate cancer immunotherapy’s response rate drops, according to new early-stage data

Dec 02 1:00pm ET Navigating JPM 2026: Biotech/biopharma trends, policy impacts & a forward look into the year sponsored by Real Chemistry Dec 03 10:30am ET AI & multi-omics for translational research sponsored by Precision for Medicine Dec 09 11:00am ET Strategic solutions for cost, time and quality challenges in drug development sponsored by Cambrex Dec 16 11:30am ET Ensure EU GMP Annex I compliance while maintaining sterile injectable manufacturing excellence & agility sponsored by Grand River Dec 17 12:00pm ET Genetic cohorting and therapeutic response in CKD: Real-world insights from RenasightIQ™ sponsored by Natera

The hematology sector heads into ASH under pressure, with data that could reshape R&D strategies and investment decisions across blood disorders. Join our expert analysis of the year’s most consequential readouts. Sign up today.

endpoints pharma New ACIP chair compares Covid requirements to Holocaust, says shots caused cancer, miscarriages FDA and Prasad's Covid vaccine death claims lack key details Belite Bio aims for first approval of Stargardt disease treatment with Phase 3 success

in case you missed it 1. UK to spend more on medicines for US tariff exemption 2. Lilly slightly lowers self-pay prices for single-dose vials of Zepbound 3. Gene writing startup Tessera strikes $150M partnership with Regeneron